Drug intelligence / Profile preview

ropivacaine + epinephrine

Development stage
Phase 4
Lead developer
AstraZeneca
Modality
Small Molecules
Administration
Epidural, Nerve Block, Local Infiltration
01

Overview

Ropivacaine + epinephrine is a combination of two active pharmaceutical ingredients used primarily for local or regional anesthesia in surgical procedures and acute pain management. Ropivacaine is an amide-type local anesthetic that works by blocking voltage-gated sodium channels on nerve fibers, thereby inhibiting the initiation and conduction of nerve impulses, resulting in loss of sensation in the targeted area[1][5][6]. Epinephrine acts as a vasoconstrictor, reducing blood flow at the injection site to potentially decrease systemic absorption of ropivacaine and prolong its local effect; however, clinical evidence suggests that adding epinephrine to ropivacaine does not significantly alter onset time, duration of action, or systemic absorption compared to ropivacaine alone[2][4][5]. The combination may be used for epidural blocks (including labor analgesia), major nerve blocks, and infiltration anesthesia. It is not marketed under a unique brand name but may be compounded for specific clinical use.

Other names
ropivacaine + epinephrine
02

Targets

ADRA1A (α1A)ADRB2 (β2)SCN1A (Voltage-gated sodium channel protein type 1 subunit alpha)

Beyond the preview

Go deeper on ropivacaine + epinephrine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ropivacaine + epinephrine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call